France Diabetes Market to be USD 3.38 Billion by 2028, Propelled by Growing Obese Population, Sedentary Lifestyles and Unhealthy Diets
21 Feb, 2023

According to Renub Research latest report, "France Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Share, Growth, Company Analysis," France's Diabetes Market is estimated to grow at a CAGR of 2.72% and reach US$ 3.38 Billion by 2028. France is among the top five countries in the European region with the highest incidence of diabetes. According to the International Diabetes Federation Report, 2017, approximately 66 Million people in Europe suffer from diabetes, which will go up to 81 million by 2045. The prevalence of diabetes is rising among all ages in France.

The rise is due to the growing obese population and unhealthy diets and lifestyles. Nearly a million people have been diagnosed with diabetes in France, according to the World Health Organization (WHO). Thus, the rising prevalence of diabetes and obesity, growing awareness regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that drive the market for diabetes drugs in France. In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applied to all the countries.

Prevalence of Type 2 Diabetes will Rise:

The factors such as rising research and development activities, as well as the rising prevalence of obesity, are propelling the demand for type 2 diabetes drugs. In addition, improved supply chain management is providing lucrative opportunities to expand the France type 2 diabetes market. According to a survey by the EU Commission, the number of individuals in France who have chronic diabetes is the greatest, and one in 10 people in France has diabetes.

Government Initiatives assist in the Management of Diabetes:

Chronic diseases, especially diabetes mellitus, are a significant priority for the French National Health Insurance (CNAMTS). The goal of the SOPHIA program is to improve the health status and the quality of life of people with diabetes and to reduce healthcare expenditure by reducing complications and comorbidity frequency. To achieve this, SOPHIA provides a comprehensive program of support, addressing both type 1 and type 2 diabetes patients, building on the pivotal role of the general physician (GP) in the healthcare system and helping them to coordinate care for their patients.

SMBG has Superiority in the Market Share due to the Rise in the Diabetes Population

Driving factors that help the dominance of SMBG market share are the increasing diabetic population in the country, Governments' and NGOs' efforts to increase awareness, increasing per capita healthcare expenditure, and availability of reimbursements in the country. For instance, France's statutory health insurance (SHI) covers 100% of it, and the number of covered patients has doubled in the past ten years. The development of technologically enhanced SMBG devices augmented with mobility, high precision, and increased dependability will positively impact device adoption.

Demand for sophisticated SMBG devices will increase as a less invasive and integrated device for disease monitoring grows. Additionally, investments in research and development result in new product launches and increased knowledge of diabetes care and management. Furthermore, technologically advanced portable and small devices offer ease in handling patients.

Competitive Landscape:

Major players competing in the France Diabetes Market are; B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care. 

Market Summary:

• Devices - Report covers France's Diabetes Market by devices in 3 viewpoints (SMBG, CGM, and Insulin Pumps).
• Key Players - All the major players have been covered from 3 Viewpoints (Company Overview, Recent Developments, and Financial Insights) B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.

About Us
Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us
Renub Research
Phone: +1-478-202-3244 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research